← Eichor
Study identifier: NCT05192122 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

Condition: Multiple Myeloma  ·  Sponsor: University of Illinois at Chicago

PhasePhase 1
Planned participants50
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

This description comes directly from the study's public registry record.

Talk to the study team

Karen Sweiss, PharmD  ·  312-996-0875  ·  ksweis2@uic.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of Illinois Cancer CenterChicago, Illinois, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05192122